Physician profile
Jairo Rodriguez
NPI 1689625741
$9,983.37
in general payments reported to CMS, 2019-2025
32 companies · $1,374 in 2025
The $1,374 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $1,272 · 2021: $1,349 · 2022: $1,976 · 2023: $785 · 2024: $2,065 · 2025: $1,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,607 · Travel and Lodging: $556 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,607.47 |
| Travel and Lodging | $556.32 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,272.04 | 2019-2023 | Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $1,079.30 | 2019-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals Lp | $825.23 | 2019-2025 | Breztri, Airsupra |
| Mylan Specialty L.P. | $730.00 | 2019-2024 | Yupelri, Yupelri |
| Intuitive Surgical, INC. | $674.16 | 2024 | |
| Pulmonx Corporation | $661.67 | 2022 | |
| Inspire Medical Systems, INC. | $649.97 | 2023-2025 | Inspire |
| Insmed, INC. | $633.44 | 2021-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $588.53 | 2021-2025 | Tyvaso |
| Electromed, INC. | $362.88 | 2022-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.05 | 2019-2024 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $287.39 | 2019-2022 | |
| Boston Scientific Corporation | $248.21 | 2022-2023 | Exalt Model D |
| Sunovion Pharmaceuticals INC. | $243.44 | 2019-2020 | |
| Ethicon INC. | $212.15 | 2024-2025 | Monarch Platform |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $163.68 | 2020-2025 | Respiratory, Home Pi Undivided |
| Verona Pharma, INC. | $152.39 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $130.52 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.01 | 2020 | |
| Baxter Healthcare | $95.79 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $82.61 | 2019-2021 | |
| Alkermes, INC. | $77.26 | 2025 | Aristada, Lybalvi |
| Pfizer INC. | $72.53 | 2020-2021 | |
| Allergan, INC. | $64.06 | 2019-2020 | |
| Abbvie INC. | $60.09 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.70 | 2025 | Caplyta |
| Regeneron Healthcare Solutions, INC. | $33.33 | 2023-2024 | Dupixent |
| Viatris Specialty LLC | $32.38 | 2025 | Yupelri |
| Genzyme Corporation | $28.68 | 2025 | |
| Medtronic, INC. | $22.62 | 2025 | Illumisite |
| Lilly USA, LLC | $16.24 | 2025 | Zepbound |
| Vapotherm INC | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jairo Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.